

Brain Cytosolic Phospholipase A₂α Mediates Angiotensin II-Induced Hypertension and Reactive Oxygen Species Production in Male Mice

Chi Young Song,¹ Nayaab S. Khan,¹ Francesca-Fang Liao,¹ Bin Wang,¹ Ji Soo Shin,¹ Joseph V. Bonventre² and Kafait U. Malik¹

BACKGROUND

Recently, we reported that angiotensin II (Ang II)-induced hypertension is mediated by group IV cytosolic phospholipase A₂α (cPLA₂α) *via* production of prohypertensive eicosanoids. Since Ang II increases blood pressure (BP) *via* its action in the subfornical organ (SFO), it led us to investigate the expression and possible contribution of cPLA₂α to oxidative stress and development of hypertension in this brain area.

METHODS

Adenovirus (Ad)-green fluorescence protein (GFP) cPLA₂α short hairpin (sh) RNA (Ad-cPLA₂α shRNA) and its control Ad-scrambled shRNA (Ad-Scr shRNA) or Ad-enhanced cyan fluorescence protein cPLA₂α DNA (Ad-cPLA₂α DNA) and its control Ad-GFP DNA were transduced into SFO of cPLA₂α^{+/+} and cPLA₂α^{-/-} male mice, respectively. Ang II (700 ng/kg/min) was infused for 14 days in these mice, and BP was measured by tail-cuff and radio telemetry. cPLA₂ activity, reactive oxygen species production, and endoplasmic reticulum stress were measured in the SFO.

RESULTS

Transduction of SFO with Ad-cPLA₂α shRNA, but not Ad-Scr shRNA in cPLA₂α^{+/+} mice, minimized expression of cPLA₂α, Ang II-induced cPLA₂α activity and oxidative stress in the SFO, BP, and cardiac and renal fibrosis. In contrast, Ad-cPLA₂α DNA, but not its control Ad-GFP DNA in cPLA₂α^{-/-} mice, restored the expression of cPLA₂α, and Ang II-induced increase in cPLA₂ activity and oxidative stress in the SFO, BP, cardiac, and renal fibrosis.

CONCLUSIONS

These data suggest that cPLA₂α in the SFO is crucial in mediating Ang II-induced hypertension and associated pathogenesis. Therefore, development of selective cPLA₂α inhibitors could be useful in treating hypertension and its pathogenesis.

Keywords: angiotensin II; blood pressure; cytosolic phospholipase A₂α; hypertension; cPLA₂α^{+/+}; cPLA₂α^{-/-}; cPLA₂α^{+/-} mice; subfornical organ.

doi:10.1093/ajh/hpy009

Angiotensin (Ang) II, the main component of the renin-angiotensin system, plays an important role in the pathogenesis of cardiovascular diseases including hypertension.¹ Ang II-induced hypertension is due to its action in the subfornical organ (SFO) of circumventricular organs resulting in increased oxidative and endoplasmic reticulum (ER) stress and activity of the sympathetic nervous system.²⁻⁴ There is a substantial body of evidence that increased reactive oxygen species (ROS) production and activation of immune cells mediate Ang II-induced hypertension and associated pathogenesis.⁵⁻⁸ Ang II also increases the activity of cytosolic phospholipase A₂ (cPLA₂) resulting in arachidonic

acid (AA) release from tissue phospholipids.^{9,10} AA is metabolized by cyclooxygenase (COX), lipoxygenase, and cytochrome P450A into various eicosanoids with prohypertensive and antihypertensive effects.¹¹⁻¹³ Prostaglandin (PG) E₂, by stimulating EP1 and EP3 receptors,¹⁴ and thromboxane A₂,¹¹ 12-, and 20-HETE,^{12,13,15,16} by their vascular actions, exert prohypertensive effects. On the other hand, PGE₂ through stimulation of EP2 and EP4 receptors,^{14,17} PGI₂,¹¹ and epoxyeicosatrienoic acids^{13,18} produce vasodepressor effects. One or more of the eicosanoids contribute to Ang II-induced hypertension.¹⁹⁻²² Ang II-salt hypertension is also dependent on COX-1 activity.²³ Intracerebroventricular

Correspondence: Kafait U. Malik (kmalik@uthsc.edu).

Initially submitted November 29, 2017; date of first revision December 21, 2017; accepted for publication January 9, 2018; online publication January 12, 2018.

¹Department of Pharmacology, College of Medicine, University of Tennessee HSC, Memphis, Tennessee, USA; ²Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

© The Author(s) 2018. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

administration of PGE₂ increases sympathetic activity, vasopressin release, and blood pressure (BP),²⁴ and the hypothalamic paraventricular excitation and sympathetic activation, *via* EP3 receptors.²⁵ Injection of PGE₂ into the rostral ventrolateral medulla also causes sympathoexcitation and pressor response *via* the EP3 receptor.²⁶ These observations suggest that the release of AA by cPLA₂, the rate-limiting step in the synthesis of eicosanoids, could be critical for Ang II-induced ROS production and hypertension.

Several types of mammalian cPLA₂ enzymes have been identified,²⁷ however, group IV cPLA₂ shows high selectivity for AA-containing phospholipids.^{27,28} cPLA₂ consists of six isoforms (cPLA₂α, -β, -γ, -δ, -ε, and -ζ) with only 30% homology, tissue distribution, and enzymatic activity.²⁸ In a previous study, we showed that the selective cPLA₂α gene disruption prevented Ang II-induced increase in urinary levels of eicosanoids, hypertension, and associated cardiovascular, renal dysfunction and inflammation, suggesting that prohypertensive eicosanoids generated from AA mediate Ang II-induced hypertension.^{29,30} However, the site of eicosanoids produced by group IV cPLA₂α, which mediate Ang II-induced hypertension, is not known. Since numerous tissues including cardiovascular, renal, brain, and immune cells produce eicosanoids that exert their effect locally, these should be formed from AA released by cPLA₂α and act at the site of action of Ang II.

PLA₂ is distributed in several regions of the brain,³¹ and Ang II increases expression of PLA₂ in the organum vasculosum of the lamina terminalis, paraventricular nucleus (PVN), nucleus of the solitary tract, and middle cerebral artery.³² The demonstration that Ang II-induced oxidative stress and hypertension is mediated *via* the COX-1-derived metabolite PGE₂ *via* EP1 receptor in the SFO³³ raises the possibility that cPLA₂α in the SFO might be critical for the action of Ang II to increase oxidative stress and BP. To test this hypothesis, we examined the localization and the effect of cPLA₂α depletion in the SFO by transduction with adenovirus (Ad)-green fluorescence protein (GFP)-cPLA₂α short hairpin (sh) RNA (Ad-cPLA₂α shRNA). We also examined its reconstitution in knockout (cPLA₂α^{-/-}) mice by transduction with Ad-enhanced cyan fluorescence protein (ECFP)-cPLA₂α DNA (Ad-cPLA₂α DNA) in the SFO. We then examined the effect of these probes on Ang II-induced hypertension and associated pathogenesis in mice. Our results show that depletion of cPLA₂α in the SFO prevents Ang II-induced hypertension, ROS and ER stress, and associated pathogenesis, while expression of cPLA₂α in cPLA₂α^{-/-} mice restores these deleterious effects of Ang II.

MATERIALS AND METHODS

Details for Materials and Methods section are in the online-only Data Supplement.

Animal experiments

All animal experiments were performed using protocols approved by the University of Tennessee Health Science Center Institutional Animal Care and Use Committee according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Experiments were conducted in 8- to 10-week-old, 20- to 25-g body weight,

wild-type (cPLA₂α^{+/+}), and cPLA₂α gene disrupted homozygous (cPLA₂α^{-/-}) male mice on BALB/c background. Ang II (700 ng/kg/min) or saline (vehicle) was infused for 14 days with micro-osmotic pumps implanted subcutaneously. Systolic BP (SBP) was measured by the noninvasive tail-cuff method, or mean arterial pressure (MAP) daily by radio telemetry. However, 2 to 3 out of 6 cPLA₂α^{-/-} BALB/c mice implanted with radio transmitters did not survive more than 8 to 10 days. We did not encounter this problem in male C57BL/6 mice. Therefore, we first confirmed the BP measurements recorded by the tail-cuff method in the male C57BL/6 mice to that obtained in BALB/c mice and then used cPLA₂α^{-/-} mice on the C57BL/6 background to further confirm BP measurements by radio telemetry.

Statistical analysis

One or 2-way analysis of variance was used to analyze the data, Tukey's post hoc test for multiple comparisons, and student's *t*-test to compare the difference between 2 groups. The values obtained from at least 3 to 5 different experiments were expressed as the mean ± SEM, *P* < 0.05 was considered statistically significant.

RESULTS

cPLA₂α gene disruption in SFO of cPLA₂α^{+/+} mice with Ad-cPLA₂α shRNA attenuated Ang II-induced increase in BP and cPLA₂ activity, but not expression of cPLA₂α, and reduced collagen accumulation in the heart and kidney

To determine the contribution of cPLA₂α in the SFO to Ang II-induced hypertension, the SFO was transduced with Ad-cPLA₂α shRNA. Infusion of Ang II by micro-osmotic pumps implanted subcutaneously increased SBP, measured by tail-cuff, in male cPLA₂α^{+/+} BALB/c and cPLA₂α^{+/+} C57BL/6 mice (Supplementary Figure S1A and B). Transduction of the SFO with Ad-cPLA₂α shRNA but not its Ad-Scr shRNA prevented Ang II-induced increase in SBP in male cPLA₂α^{+/+} BALB/c mice (Figure 1a). SBP was not altered by the adenoviruses during vehicle infusion (Figure 1a). Ad-cPLA₂α shRNA but not its Ad-Scr shRNA also prevented Ang II-induced increase in mean arterial BP (MAP) measured by radio telemetry in cPLA₂α^{+/+} C57BL/6 mice (Figure 1b). Transduction of the SFO with Ad probes was confirmed by expression of GFP in the SFO (Supplementary Figure S2A). cPLA₂α expression in the SFO was abolished by Ad-cPLA₂α shRNA but not Ad-Scr shRNA as determined by cPLA₂α immunoreactivity using mouse anti-cPLA₂ antibody in BALB/c mice (Figure 1c and d), and by RT-PCR in BALB/c and C57BL/6 mice (Supplementary Figures S2B and S3A, respectively). Ang II also increased cPLA₂ activity measured by increased phospho-cPLA₂ immunoreactivity in the SFO transduced with Ad-Scr shRNA, but not with Ad-cPLA₂α shRNA in BALB/c (Figure 1c and d), and C57BL/6 mice (Supplementary Figure S3B and C). Transduction of the SFO with Ad-Scr shRNA or Ad-cPLA₂α shRNA did not alter expression of cPLA₂α in the PVN, heart, and kidney examined in BALB/c mice (Supplementary Figure S2C–E).

Ang II is known to cause cardiac and renal fibrosis.^{29,30} To determine if the alteration in cPLA₂α expression in the




Figure 1. cPLA_{2α} gene disruption in subfornical organ (SFO) of cPLA_{2α}^{+/+} mice with adenovirus (Ad)-green fluorescence protein (GFP)-cPLA_{2α} shirt hairpin (sh) RNA (Ad-cPLA_{2α} shRNA) abrogates Ang II-induced increase in blood pressure (BP) and cPLA_{2α} phosphoimmunoreactivity. Ad-GFP scramble (Scr) shRNA (Ad-Scr shRNA) or Ad-cPLA_{2α} shRNA was transduced into SFO. (a) systolic blood pressure (SBP) was measured by tail-cuff in BALB/c mice. (b) Mean arterial blood pressure (MAP) was measured by radio telemetry in C57BL/6 mice. (c) Expression of cPLA_{2α}, and its activity measured by its phosphorylation in SFO of BALB/c mice by immunohistochemical method. Scale bars: 50 μm. (d) Quantified data. Data are expressed as mean ± SEM. n = 5 per group. *, **P < 0.05, Ad-Scr shRNA-Ang II vs. Ad-Scr shRNA-Veh (Vehicle); †P < 0.05, Ad-cPLA_{2α} shRNA-Ang II vs. Ad-Scr shRNA-Ang II in cPLA_{2α}^{+/+} BALB/c mice (a) and cPLA_{2α}^{+/+} C57BL/6 mice (b). #P < 0.05, Ad-cPLA_{2α} shRNA vs. Ad-Scr shRNA.

SFO also affects the action of Ang II on cardiac and renal fibrosis, we examined the accumulation of collagen in these tissues in BALB/c mice. cPLA_{2α} gene disruption in the SFO of cPLA_{2α}^{+/+} mice by transduction with Ad-cPLA_{2α} shRNA but not its Ad-Scr shRNA control infused with Ang II minimized accumulation of collagen in the heart and kidney (Supplementary Figure S4A and B).

Transduction with Ad-ECFP-cPLA_{2α} DNA, but not Ad-GFP DNA in the SFO of cPLA_{2α}^{-/-} mice restored the effect of Ang II to increase BP

Ang II failed to increase BP in cPLA_{2α}^{-/-} BALB/c mice (Supplementary Figure S1). Transduction with Ad-cPLA_{2α}

DNA but not Ad-GFP DNA in the SFO of cPLA_{2α}^{-/-} BALB/c mice restored the effect of Ang II to increase SBP measured by tail-cuff (Figure 2a). Ang II also increased MAP measured by radio telemetry in cPLA_{2α}^{-/-} C57BL/6 mice transduced with Ad-cPLA_{2α} DNA, but not Ad-GFP DNA in the SFO (Figure 2b). The localization of ECFP-cPLA_{2α} and GFP in the SFO transduced with Ad-cPLA_{2α} DNA and Ad-GFP DNA, respectively, was confirmed by their fluorescence (Supplementary Figure S5A), and by RT-PCR in BALB/c (Supplementary Figure S5B) and C57BL/6 mice (Supplementary Figures S5A and S6A), and by immunohistochemistry using anti-cPLA_{2α} antibody in BALB/c (Figure 2c and d) and C57BL/6 (Supplementary Figure S6B and C) mice. Ang II did not alter expression of




Figure 2. cPLA₂α gene transduction in subfornical organ (SFO) of cPLA₂α^{-/-} mice with adenovirus (Ad)-enhanced cyan fluorescence protein (ECFP)-cPLA₂α DNA (Ad-cPLA₂α DNA) restores Ang II-induced increase in blood pressure (BP) and cPLA₂ activity. Ad-green fluorescence protein (GFP) (Ad-GFP) DNA or Ad-cPLA₂α DNA was transduced into SFO. **(a)** Systolic blood pressure (SBP) was measured by tail-cuff in cPLA₂α^{-/-} BALB/c mice. **(b)** Mean arterial blood pressure (MAP) was measured by radio telemetry in cPLA₂α^{-/-} C57BL/6 mice. **(c)** Expression, and activation of cPLA₂ in SFO of BALB/c mice were measured by immunohistochemical method. Scale bars: 50 μm. **(d)** Quantified data. Data are expressed as mean ± SEM. *n* = 5 per group. *, ***P* < 0.05, Ad-cPLA₂α DNA-Ang II vs. Ad-cPLA₂α DNA-Veh (vehicle); †*P* < 0.05, Ad-cPLA₂α DNA-Ang II vs. Ad-GFP DNA-Ang II in cPLA₂α^{-/-} BALB/c and C57BL/6 mice. #*P* < 0.05, Ad-cPLA₂α DNA vs. Ad-GFP DNA.

cPLA₂α, but it increased the cPLA₂ activity, measured by phospho-cPLA₂ immunoreactivity in the SFO transduced with Ad-cPLA₂α DNA, but not Ad-GFP DNA in BALB/c mice (Figure 2c and d). cPLA₂α mRNA expression in the PVN, heart, and kidney that was absent in cPLA₂α^{-/-} BALB/c, was not altered by transduction of the SFO with Ad-GFP DNA or Ad-cPLA₂α DNA during infusion of Ang II (Supplementary Figure S5C-E).

We also determined the effect of Ang II on collagen accumulation in the heart and kidney of BALB/c cPLA₂α^{-/-} mice transduced with Ad-cPLA₂α DNA and Ad-GFP DNA in the SFO, and found collagen accumulation in the former but not the latter group of mice (Supplementary Figure S7A and B).

Transduction of SFO with cPLA₂α shRNA in cPLA₂α^{+/+} mice attenuated, and Ad-cPLA₂α DNA in cPLA₂α^{-/-} mice restored Ang II-induced increase in ROS production

These studies were conducted in BALB/c mice that were infused with Ang II or its vehicle for the measurement of BP as described above. Infusion of Ang II also stimulated the production of ROS as indicated by enhanced 2-hydroxyethidium fluorescence in the SFO generated after staining with dihydroethidium as described,⁴ in cPLA₂α^{+/+} mice but not in cPLA₂α^{-/-} mice (Figure 3a and b). Transduction of the SFO with Ad-cPLA₂α shRNA but not its Ad-Scr shRNA inhibited dihydroethidium staining (Figure 3c and d) in cPLA₂α^{+/+} mice. Infusion of Ang II in cPLA₂α^{-/-} mice failed




Figure 3. Transduction of subfornical organ (SFO) with Ad-cPLA₂α shRNA attenuates, and Ad-cPLA₂α DNA restores Ang II-induced increase in reactive oxygen species (ROS) production in cPLA₂α^{+/+} BALB/c mice. ROS production was determined using dihydroethidium (DHE). (a) and (b) Ang II-induced increase in ROS production in SFO in cPLA₂α^{+/+} but not cPLA₂α^{-/-} BALB/c mice. (c) and (d) Transduction of Ad-cPLA₂α shRNA in SFO abrogated Ang II-induced increase in ROS production in cPLA₂α^{+/+} BALB/c mice. (e) and (f) Transduction of Ad-cPLA₂α DNA in SFO restored Ang II-induced increase in ROS production in cPLA₂α^{-/-} BALB/c mice. Panels a, c, and e, scale bars: 50 μm. Panels b, d, and f, Quantified data (A. U., arbitrary units). Data are expressed as mean ± SEM. *n* = 5 per group. **P* < 0.05, Ang II vs. Veh (vehicle); %*P* < 0.05, cPLA₂α^{-/-}-Ang II vs. cPLA₂α^{+/+}-Ang II; ***P* < 0.05, Ad-Scr shRNA-Ang II vs. Ad-Scr shRNA-Veh; †*P* < 0.05, Ad-cPLA₂α shRNA-Ang II vs. Ad-Scr shRNA-Ang II; #*P* < 0.05, Ad-cPLA₂α DNA-Ang II vs. Ad-GFP DNA-Ang II.

to increase dihydroethidium staining, whereas transduction with Ad-cPLA₂α DNA, but not Ad-GFP DNA in the SFO of these mice restored the effect of Ang II to increase dihydroethidium staining (Figure 3e and f).

Ang II increased ER stress marker expression in SFO of cPLA₂α^{+/+} but not cPLA₂α^{-/-} mice

Ang II also increased ER stress as indicated by increased mRNA levels of markers of ER stress glucose-related protein 78 (GRP78), and C/EBP homologous protein (CHOP) in cPLA₂α^{+/+} BALB/c mice (Figure 4a). Infusion of Ang II in cPLA₂α^{-/-} mice did not induce mRNA levels of GRP78 and CHOP (Figure 4b).

Partial cPLA₂α gene disruption (cPLA₂α^{+/-}) also prevented Ang-II-induced increase in BP in mice

Ang II did not increase BP in cPLA₂α^{-/-} BALB/c and C57BL/6 male mice (Supplementary Figure S1A and B). To determine if partial cPLA₂α gene disruption reduces Ang II-induced increase in BP, we examined its effect in heterozygous cPLA₂α (cPLA₂α^{+/-}) C57BL/6 male mice. Ang II (700 ng/kg/min) increased SBP measured by tail-cuff in cPLA₂α^{+/+} but not cPLA₂α^{+/-} C57BL/6 male mice (Supplementary Figure S8). cPLA₂α mRNA expression in the SFO, heart, and kidney of C57BL/6 cPLA₂α^{+/-} mice was lower (60–80%) than in C57BL/6 cPLA₂α^{+/+} mice (Supplementary Figure S9).

DISCUSSION

The major findings of this study are that SFO is the principal site of action of cPLA₂α in mediating the action of Ang II: (i) to increase BP; (ii) to stimulate ROS production and ER stress in the SFO, and (iii) to cause cardiac and renal fibrosis. These findings are based on our demonstration that cPLA₂α selectively releases AA from tissue phospholipids,^{27,28} is expressed in the SFO, and that Ang II increased cPLA₂ activity, as determined by its phosphoimmunoreactivity without altering its expression. However, Ang II has been shown to increase expression of phospholipase A₂ in the organum vasculosum of the lamina terminalis, PVN, nucleus of the solitary tract, and middle cerebral artery of the rat.³² Whether this increase in phospholipase A₂ expression by Ang II in these tissues represents primarily increased expression of cPLA₂α, or other isoforms of phospholipase A₂ is not known. We have previously reported that Ang II increases BP, and sympathetic outflow as determined from heart rate variability by power spectral analysis in cPLA₂α^{+/+} but not cPLA₂α^{-/-} BALB/c mice.²⁹ Our demonstration that cPLA₂α gene disruption in the SFO by Ad-cPLA₂α shRNA, but not its Ad-Scr shRNA, reduced cPLA₂α expression and phospho-cPLA₂ immunoreactivity and prevented Ang II-induced increase in BP in cPLA₂α^{+/+} BALB/c and C57BL/6 mice, suggests that cPLA₂α in the SFO is critical for Ang II-induced hypertension. Although Ang II 700 ng/kg/min used in this study would be expected to cause the increase in BP by its direct vascular action but it appears that cPLA₂α in the SFO is primarily responsible for this effect of Ang II. Further supporting this conclusion was our finding




Figure 4. Ang II increases endoplasmic reticulum (ER) stress marker expression in the subfornical organ (SFO) of BALB/c cPLA₂α^{+/+} but not cPLA₂α^{-/-} mice. RNA was isolated from SFO, and real-time PCR (RT-PCR) was performed for glucose-related protein 78 (GRP78), and C/EBP homologous protein (CHOP). **(a)** mRNA expression of GRP78 and CHOP in SFO of cPLA₂α^{+/+} mice. **(b)** mRNA expression of GRP78 and CHOP in SFO of cPLA₂α^{-/-} mice. **P* < 0.05, Ang II vs. Veh (vehicle) (*n* = 4). Data are expressed as mean ± SEM.

that in cPLA₂α^{-/-} BALB/c and C57BL/6 mice, reconstitution of cPLA₂α in the SFO by transduction with Ad-cPLA₂α DNA but not Ad-GFP DNA increased cPLA₂α expression and phospho-cPLA₂ immunoreactivity, and restored the effect of Ang II to increase BP. That cPLA₂α protein formed by transduction with Ad-cPLA₂α DNA, but not Ad-GFP DNA is capable of releasing AA has been confirmed in vascular smooth muscle cells.³⁴ The decrease in the expression of cPLA₂α in the SFO transduced with Ad-Scr shRNA in cPLA₂α^{+/+} mice, and the increase with Ad-cPLA₂α DNA in cPLA₂α^{-/-} mice was selective because its expression in the PVN, heart and kidney were not altered in these mice. Ang II stimulates ROS production and ER stress in the SFO that leads to an increase in BP,^{3,4} most likely by increasing sympathetic activity.² The increase in BP produced by Ang II 600 ng/kg/min, which is comparable to that obtained in the present study by 700 ng/kg/min of this peptide, is prevented by intracerebral ventricle administration of superoxide scavenger Ad-CuZn superoxide dismutase.⁴ Since (i) depletion of cPLA₂α by Ad-cPLA₂α shRNA in the SFO of cPLA₂α^{+/+} mice reduced, and (ii) expression of cPLA₂α by transduction with Ad-cPLA₂α DNA in cPLA₂α^{-/-} BALB/c mice restored Ang II-induced ROS production and ER stress, this suggests that cPLA₂α expression and activity mediates the effect of Ang II on ROS production and ER stress. Whether alteration in cPLA₂α activity by Ang II in SFO also affects the ROS production and ER stress in PVN and rostral ventrolateral medulla remains to be determined. Ang II is known to produce cardiac and renal fibrosis, which is dependent on prohypertensive eicosanoids generated by activation of cPLA₂α.^{29,30} Our demonstration that Ang II-induced cardiac and renal fibrosis, as indicated by collagen accumulation, was minimized by depletion of cPLA₂α in the SFO by transduction with Ad-cPLA₂α shRNA in cPLA₂α^{+/+} BALB/c mice suggests that cPLA₂α activation in the SFO contributes to this action of Ang II. Supporting this view was our observation that reconstitution of cPLA₂α by Ad-cPLA₂α DNA in cPLA₂α^{-/-} BALB/c mice caused Ang II to produce cardiac and renal fibrosis. Whether attenuation of Ang II-induced cardiac and renal fibrosis caused by decreased expression of cPLA₂α by Ad-cPLA₂α shRNA in the SFO of cPLA₂α^{+/+} mice and restoration of fibrosis in

these tissues by expression of cPLA₂α by Ad-cPLA₂α DNA in cPLA₂α^{-/-} mice, which could be due to changes in BP and/or sympathetic activity, remains to be determined.

cPLA₂α activation by Ang II releases AA that is metabolized by COX, lipoxygenase, and cytochrome P450A into eicosanoids with prohypertensive and antihypertensive effects.^{11–22} Previously, we reported that prohypertensive eicosanoids generated by cPLA₂α activation contributed to Ang II-induced hypertension and associated cardiac and renal pathogenesis.^{29,30} COX-1 inhibitor SC560 minimized Ang II-salt-induced hypertension which is associated with the increased sympathetic activity.³² Decrease in COX-2 expression by IL-10 in PVN is related to reduced neuronal sympathetic excitation in heart failure in rats after myocardial infarction.³⁵ On the other hand, proinflammatory cytokines stimulate COX-2 expression in perivascular macrophages,³⁶ and when injected in the SFO increase BP, heart rate, and renal sympathetic activity.³⁷ Therefore, Ang II *via* production of proinflammatory cytokines could increase COX activity and PGE₂ synthesis. Reduction in COX-1 and COX-2 expression by their respective siRNA in PVN also reduces deoxycorticosterone-induced hypertension.³⁸ COX-generated AA metabolite PGE₂ injected into the cerebroventricular system^{24,25} or rostral ventrolateral medulla²⁶ increases BP and sympathetic activity *via* EP₃ receptors, respectively.^{25,26} Ang II-induced increase in BP is inhibited in both EP₁ and EP₃ receptor knockout mice or by EP₁ and EP₃ receptor antagonists.^{19,21} PGE₂ generated by COX-1 in the SFO *via* the EP₁ receptor is required for ROS generation and hypertension caused by Ang II.³³ AA-metabolizing enzymes are constitutively active, and the rate-limiting step in the production of eicosanoids is the availability of AA. Therefore, cPLA₂α activation by Ang II in the SFO appears to be critical for AA release resulting in the production of PGE₂, and generation of ROS and ER stress that increases BP and results in cardiac and renal fibrosis. The contribution in Ang II-induced hypertension of cPLA₂α in the PVN and rostral ventrolateral medulla where PGE₂ *via* EP₃ receptors increases BP^{25,26} remains to be investigated and is one of the limitations of the present study. Like in our study in cPLA₂α^{-/-} mice, the COX1 or EP₁ receptor gene disruption

or the central administration of their pharmacological inhibitors attenuated the increase in BP produced by Ang II (600 ng/kg/min)³³ that was comparable to that obtained in the present study. At present, we have no explanation how the central cPLA₂α/COX1/EP1 receptor in SFO masks the direct vasoconstrictor effect of Ang II. Further studies are required to determine if alteration in cPLA₂α/COX/EP receptors in SFO and other brain areas also prevent the effect of bolus injections or short-term infusion of Ang II.

An important finding in our study was that Ang II also failed to increase BP in the partially cPLA₂α gene-disrupted mice (cPLA₂α^{+/-}) expressing reduced cPLA₂α mRNA in the heart, kidney, and SFO in C57BL/6 mice. These observations further support the critical role of cPLA₂α in Ang II-induced hypertension. Further studies on different levels of cPLA₂α expression or its copy number in the SFO and other tissues should allow the determination of its relationship to BP in various models of hypertension and associated pathogenesis. cPLA₂α gene disruption also prevented hypertension produced by the inhibitor of nitric oxide synthesis, L-NG-nitroarginine methyl ester,³⁹ that is dependent on Ang II.⁴⁰ Our preliminary data obtained in C57BL/6 mice showed that cPLA₂α gene disruption abolished deoxycorticosterone-acetate-salt-induced hypertension and associated cardiac and renal fibrosis (C Y Song and K U Malik, unpublished results).

In conclusion, this study demonstrates that cPLA₂α in the SFO is crucial in mediating the effect of systemic Ang II to cause ROS production and ER stress and hypertension, most likely by releasing AA and metabolizing it *via* COX producing PGE₂. Our finding that the partial cPLA₂α gene disruption (cPLA₂α^{+/-} mice) also prevented Ang II-induced hypertension supports the notion that cPLA₂α activation is pivotal for the development of Ang II-induced hypertension. Therefore, development of selective orally active inhibitors of cPLA₂α could be useful in the treatment of hypertension and its pathogenesis.

SUPPLEMENTARY MATERIAL

Supplementary materials are available at *American Journal of Hypertension* online.

ACKNOWLEDGMENTS

We thank Dr Richard Redfearn of the Office Scientific Writing in the Office of Research at UTHSC for editorial assistance. This work was supported by the National Institutes of Health National Heart, Lung, and Blood Institute grants R01HL-19134-42 (K.U.M.) and R21-NINDS-NS091593 (J.V.B.). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Heart, Lung, and Blood Institute.

DISCLOSURE

The authors declared no conflict of interest.

REFERENCES

- Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. *Pharmacol Rev* 2007; 59:251–287.
- Campese VM, Shaohua Y, Huiquin Z. Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity. *Hypertension* 2005; 46:533–539.
- Young CN, Cao X, Guruju MR, Pierce JP, Morgan DA, Wang G, Iadecola C, Mark AL, Davisson RL. ER stress in the brain subfornical organ mediates angiotensin-dependent hypertension. *J Clin Invest* 2012; 122:3960–3964.
- Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. *Circ Res* 2004; 95:210–216.
- Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. *Circulation* 1997; 95:588–593.
- Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? *Hypertension* 2004; 44:248–252.
- Loperena R, Harrison DG. Oxidative stress and hypertensive diseases. *Med Clin North Am* 2017; 101:169–193.
- Schiffirin EL. Immune mechanisms in hypertension and vascular injury. *Clin Sci (Lond)* 2014; 126:267–274.
- Rao GN, Lassègue B, Alexander RW, Griendling KK. Angiotensin II stimulates phosphorylation of high-molecular-mass cytosolic phospholipase A₂ in vascular smooth-muscle cells. *Biochem J* 1994; 299 (Pt 1):197–201.
- Muthalif MM, Benter IF, Uddin MR, Harper JL, Malik KU. Signal transduction mechanisms involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells. *J Pharmacol Exp Ther* 1998; 284:388–398.
- McGiff JC. Prostaglandins, prostacyclin, and thromboxanes. *Annu Rev Pharmacol Toxicol*. 1981; 21:479–509.
- Kuhn H, Chaitidis P, Roffeis J, Walther M. Arachidonic Acid metabolites in the cardiovascular system: the role of lipoxygenase isoforms in atherogenesis with particular emphasis on vascular remodeling. *J Cardiovasc Pharmacol* 2007; 50:609–620.
- Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. *Physiol Rev* 2002; 82:131–185.
- Zhang Y, Guan Y, Schneider A, Brandon S, Breyer RM, Breyer MD. Characterization of murine vasopressor and vasodepressor prostaglandin E₂ receptors. *Hypertension* 2000; 35:1129–1134.
- Nasjletti A. Arthur C. Corcoran Memorial Lecture. The role of eicosanoids in angiotensin-dependent hypertension. *Hypertension* 1998; 31:194–200.
- Wu CC, Gupta T, Garcia V, Ding Y, Schwartzman ML. 20-HETE and blood pressure regulation: clinical implications. *Cardiol Rev* 2014; 22:1–12.
- Audoly LP, Tilley SL, Goulet J, Key M, Nguyen M, Stock JL, McNeish JD, Koller BH, Coffman TM. Identification of specific EP receptors responsible for the hemodynamic effects of PGE₂. *Am J Physiol* 1999; 277:H924–H930.
- Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. *Nat Rev Drug Discov* 2009; 8:794–805.
- Chen L, Miao Y, Zhang Y, Dou D, Liu L, Tian X, Yang G, Pu D, Zhang X, Kang J, Gao Y, Wang S, Breyer MD, Wang N, Zhu Y, Huang Y, Breyer RM, Guan Y. Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response *via* decreasing arterial contractility. *Arterioscler Thromb Vasc Biol* 2012; 32:3024–3032.
- Francois H, Athirakul K, Mao L, Rockman H, Coffman TM. Role for thromboxane receptors in angiotensin-II-induced hypertension. *Hypertension* 2004; 43:364–369.
- Guan Y, Zhang Y, Wu J, Qi Z, Yang G, Dou D, Gao Y, Chen L, Zhang X, Davis LS, Wei M, Fan X, Carmosino M, Hao C, Imig JD, Breyer RM, Breyer MD. Antihypertensive effects of selective prostaglandin E₂ receptor subtype 1 targeting. *J Clin Invest* 2007; 117:2496–2505.
- Wang F, Lu X, Peng K, Du Y, Zhou SF, Zhang A, Yang T. Prostaglandin E-prostanoid4 receptor mediates angiotensin II-induced (pro)renin receptor expression in the rat renal medulla. *Hypertension* 2014; 64:369–377.

23. Asirvatham-Jeyaraj N, King AJ, Northcott CA, Madan S, Fink GD. Cyclooxygenase-1 inhibition attenuates angiotensin II-salt hypertension and neurogenic pressor activity in the rat. *Am J Physiol Heart Circ Physiol* 2013; 305:H1462–H1470.
24. Okuno T, Lindheimer MD, Oparil S. Central effects of prostaglandin E₂ on blood pressure and plasma renin activity in rats. Role of the sympathoadrenal system and vasopressin. *Hypertension* 1982; 4:809–816.
25. Zhang ZH, Yu Y, Wei SG, Nakamura Y, Nakamura K, Felder RB. EP₃ receptors mediate PGE₂-induced hypothalamic paraventricular nucleus excitation and sympathetic activation. *Am J Physiol Heart Circ Physiol* 2011; 301:H1559–H1569.
26. Rezaq S, Abdel-Rahman AA. Rostral ventrolateral medulla EP₃ receptor mediates the sympathoexcitatory and pressor effects of prostaglandin E₂ in conscious rats. *J Pharmacol Exp Ther* 2016; 359:290–299.
27. Burke JE, Dennis EA. Phospholipase A₂ structure/function, mechanism, and signaling. *J Lipid Res* 2009; 50(Suppl):S237–S242.
28. Leslie CC. Cytosolic phospholipase A₂: physiological function and role in disease. *J Lipid Res* 2015; 56:1386–1402.
29. Khan NS, Song CY, Jennings BL, Estes AM, Fang XR, Bonventre JV, Malik KU. Cytosolic phospholipase A₂α is critical for angiotensin II-induced hypertension and associated cardiovascular pathophysiology. *Hypertension* 2015; 65:784–792.
30. Khan NS, Song CY, Thirunavukkarasu S, Fang XR, Bonventre JV, Malik KU. Cytosolic phospholipase A₂α is essential for renal dysfunction and end-organ damage associated with angiotensin II-induced hypertension. *Am J Hypertens* 2016; 29:258–265.
31. Balboa MA, Varela-Nieto I, Killermann Lucas K, Dennis EA. Expression and function of phospholipase A(2) in brain. *FEBS Lett* 2002; 531:12–17.
32. Asirvatham-Jeyaraj N, Fink GD. Possible role for brain prostanoid pathways in the development of angiotensin II-salt hypertension in rats. *Am J Physiol Regul Integr Comp Physiol* 2016; 311:R232–R242.
33. Cao X, Peterson JR, Wang G, Anrather J, Young CN, Guruju MR, Burmeister MA, Iadecola C, Davisson RL. Angiotensin II-dependent hypertension requires cyclooxygenase 1-derived prostaglandin E₂ and EP₁ receptor signaling in the subfornical organ of the brain. *Hypertension* 2012; 59:869–876.
34. Pavicevic Z, Leslie CC, Malik KU. cPLA₂ phosphorylation at serine-515 and serine-505 is required for arachidonic acid release in vascular smooth muscle cells. *J Lipid Res* 2008; 49:724–737.
35. Yu Y, Zhang ZH, Wei SG, Chu Y, Weiss RM, Heistad DD, Felder RB. Central gene transfer of interleukin-10 reduces hypothalamic inflammation and evidence of heart failure in rats after myocardial infarction. *Circ Res* 2007; 101:304–312.
36. Yu Y, Zhang ZH, Wei SG, Serrats J, Weiss RM, Felder RB. Brain perivascular macrophages and the sympathetic response to inflammation in rats after myocardial infarction. *Hypertension* 2010; 55:652–659.
37. Wei SG, Yu Y, Zhang ZH, Felder RB. Proinflammatory cytokines upregulate sympathoexcitatory mechanisms in the subfornical organ of the rat. *Hypertension* 2015; 65:1126–1133.
38. Sriramula S, Xia H, Xu P, Lazartigues E. Brain-targeted angiotensin-converting enzyme 2 overexpression attenuates neurogenic hypertension by inhibiting cyclooxygenase-mediated inflammation. *Hypertension* 2015; 65:577–586.
39. Tanaka K, Yamamoto Y, Ogino K, Tsujimoto S, Saito M, Uozumi N, Shimizu T, Hisatome I. Cytosolic phospholipase A₂α contributes to blood pressure increases and endothelial dysfunction under chronic NO inhibition. *Arterioscler Thromb Vasc Biol* 2011; 31:1133–1138.
40. Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. *Hypertension* 1993; 21:660–666.